Mcl-1 (myeloid cell leukemia-1) is an anti-apoptotic protein that keeps cells alive by blocking their built-in self-destruct program, and cancer cells routinely hijack it to survive treatments that should kill them. It belongs to the BCL-2 family of proteins that regulate whether a cell lives or dies, but Mcl-1 stands apart from its relatives in ways that make it both indispensable to healthy tissues and a stubborn obstacle in oncology. The tension between those two roles is exactly what makes Mcl-1 one of the more fascinating and frustrating targets in modern cancer research.
What Mcl-1 Does in Healthy Cells
Before Mcl-1 became a cancer target, it was recognized as essential for normal development. Mice engineered to lack the Mcl-1 gene entirely die before they can even implant in the uterus. Their embryos stall at the blastocyst stage and fail to attach to the uterine wall, pointing to a role that goes beyond simply preventing cell death; the embryos showed no increase in apoptosis but could not mature properly.1Genes & Development. Mcl-1 deficiency results in peri-implantation embryonic lethality Among all the pro-survival genes in the BCL-2 family, Mcl-1 is one of only two whose complete deletion is lethal at the embryonic stage.2PubMed Central. Physiological Functions of Mcl-1: Insights From Genetic Mouse Models
Later in life, Mcl-1 remains critical for specific cell populations that turn over rapidly or face constant stress. Blood-forming stem cells in the bone marrow depend on it: when researchers switched off Mcl-1 in adult mice, bone marrow was effectively destroyed and the earliest progenitor populations, including hematopoietic stem cells, disappeared.3PubMed. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells Neutrophils, the white blood cells that are first responders to infection, are also critically dependent on Mcl-1 for survival.4PubMed Central. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages And in the liver, deleting Mcl-1 specifically from hepatocytes triggers spontaneous cell death severe enough to cause liver damage and, over time, even liver cancer from the compensatory proliferation that follows.5PubMed Central. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice
The picture that emerges is one of a protein woven deeply into tissue maintenance. Mcl-1 is not a luxury; it is load-bearing infrastructure for blood, immune, liver, and embryonic tissues. That breadth of dependence is what makes targeting it in cancer so tricky: you cannot simply shut it off everywhere without collateral damage.
Roles Beyond Blocking Cell Death
For years, researchers thought of Mcl-1 purely as a survival signal that prevented apoptosis. That changed when a shorter form of the protein was found inside the mitochondrial matrix, the innermost compartment of the cell’s energy factories. This truncated version of Mcl-1 turned out to be necessary for mitochondrial fusion, normal energy production, membrane voltage maintenance, and the structural integrity of the inner folds (cristae) where respiration takes place.6PubMed Central. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration In other words, Mcl-1 is not just keeping cells from dying; it is actively helping them generate energy.
Mcl-1 also shows up where DNA has been damaged. When cells are hit with agents that break their DNA strands, Mcl-1 accumulates at the damage sites and helps coordinate the repair response. Cells that lack Mcl-1 accumulate more chromosomal abnormalities after repeated rounds of DNA damage and recovery, suggesting the protein plays a genuine role in maintaining genome stability.7PubMed Central. MCL-1 localizes to sites of DNA damage and regulates DNA damage response These non-apoptotic functions matter because they mean Mcl-1 loss does not just flip a death switch; it degrades fundamental cell processes like energy metabolism and DNA repair, potentially explaining some of the severe tissue damage seen in knockout experiments.
A Protein on a Very Short Leash
One of the most distinctive features of Mcl-1 is how rapidly the cell destroys it. Most pro-survival proteins in the BCL-2 family are relatively stable, lingering in the cell for hours or days. Mcl-1, by contrast, has a short half-life, meaning the cell must constantly produce it to maintain protection. The moment production slows down or degradation speeds up, Mcl-1 levels plummet and the cell becomes vulnerable to apoptosis.8PubMed Central. Understanding MCL1: from cellular function and regulation to pharmacological inhibition
This rapid turnover is governed primarily by the ubiquitin-proteasome system. At least six different enzymes have been identified that can tag Mcl-1 with ubiquitin chains, flagging it for destruction by the proteasome. Whether Mcl-1 gets tagged depends heavily on its phosphorylation state: certain chemical marks on the protein either stabilize it or mark it for degradation.9Cell Death & Disease. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options The N-terminal region of Mcl-1 is uniquely loaded with sites for ubiquitination, phosphorylation, and cleavage, making it the most heavily regulated stretch of any BCL-2 family protein.10PubMed. Mcl-1; the molecular regulation of protein function
A specific example of how phosphorylation and stability interconnect: the ERK signaling pathway can add phosphate groups to Mcl-1 at two particular positions, which allows another protein called Pin1 to bind and stabilize Mcl-1. In breast cancer cells, blocking this ERK-Pin1 axis with the drug sorafenib destabilized Mcl-1 and made the cells more sensitive to chemotherapy.11PubMed Central. Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer Cancer cells, in short, have learned to exploit these phosphorylation switches to keep Mcl-1 levels artificially high.
Two Faces of the Same Gene
The Mcl-1 gene does not produce just one protein. Through alternative splicing, cells can generate two main versions from the same stretch of DNA. The long form, Mcl-1L, is the well-known anti-apoptotic protein that promotes survival. The short form, Mcl-1S, does the opposite: it functions as a pro-apoptotic molecule that pushes cells toward death.12PubMed Central. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells Mcl-1S structurally resembles a class of pro-death proteins called BH3-only proteins, which activate the cell’s apoptotic machinery.13Cell Death & Disease. Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer
The balance between these two splice forms has real clinical significance. In gastric cancer patients, researchers found that tumors tipped the ratio toward more Mcl-1L and less Mcl-1S, and this imbalance correlated with greater tumor growth and worse survival outcomes.14PubMed Central. Modification of Mcl-1 alternative splicing induces apoptosis and suppresses tumor proliferation in gastric cancer This raises an intriguing therapeutic angle: rather than blocking Mcl-1 protein directly, it might be possible to shift the splicing machinery so that cells produce more of the death-promoting short form and less of the survival-promoting long form. Some chemical compounds have shown the ability to do exactly this in laboratory settings, though this approach has not yet reached the clinic.
How Cancer Cells Exploit Mcl-1
Given that Mcl-1 is a brake on cell death, it is no surprise that cancer cells keep that brake pressed as hard as possible. Mcl-1 overexpression has been documented across a range of cancers, including leukemias, lymphomas, and solid tumors. Cancer cells achieve high Mcl-1 levels through several routes: amplifying the gene, ramping up transcription, stabilizing the protein by altering phosphorylation, or interfering with the ubiquitin-tagging enzymes that would normally mark it for destruction.9Cell Death & Disease. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options
The practical consequence is that cells with high Mcl-1 levels resist chemotherapy and other treatments designed to trigger apoptosis. Because the protein functions as a rapid sensor of cell stress, its overexpression essentially numbs the cell to danger signals. Treatments that would normally push a cancer cell past the point of no return get absorbed without effect when Mcl-1 is abundant enough to soak up all the pro-death signals.8PubMed Central. Understanding MCL1: from cellular function and regulation to pharmacological inhibition
The Venetoclax Resistance Problem
Venetoclax, a drug that blocks BCL-2 (a close relative of Mcl-1), has been a breakthrough treatment for certain blood cancers. But its success has thrown the Mcl-1 problem into sharp relief. In acute myeloid leukemia (AML), Mcl-1 is commonly upregulated and is often the primary mechanism by which cancer cells become resistant to venetoclax.15PubMed Central. A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia When venetoclax shuts down BCL-2, cancer cells that still have plenty of Mcl-1 simply shift their survival dependence to that protein instead.
Recent work has uncovered one way this happens at the molecular level. Cancer cells that acquire venetoclax resistance show elevated levels of reactive oxygen species (superoxide), which activate a signaling pathway that adds a stabilizing phosphorylation mark to Mcl-1 at a specific position. Cells engineered to carry a version of Mcl-1 that cannot be phosphorylated at that site remained sensitive to venetoclax, confirming that this single modification is critical for resistance.16Leukemia. Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies The finding is important because it suggests that targeting the phosphorylation pathway, rather than Mcl-1 itself, could be another way to restore venetoclax sensitivity.
Targeting Mcl-1 Directly
The pharmaceutical industry has invested heavily in developing drugs that block Mcl-1 the way venetoclax blocks BCL-2. These are designed as BH3 mimetics, small molecules that wedge into the binding groove on Mcl-1’s surface and prevent it from sequestering pro-death proteins. Early drug-discovery efforts screened chemical libraries and identified compounds with selectivity for Mcl-1 over its relatives BCL-XL and BCL-2, aided by structural studies that revealed subtle differences in the binding pockets.17PubMed. Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1
More recent selective Mcl-1 inhibitors, such as S63845, have shown promise in laboratory studies. When combined with BCL-2/BCL-XL inhibitors or drugs that block the MAPK signaling pathway, S63845 enhanced both apoptosis and differentiation in AML cell lines, a dual effect that makes the approach particularly appealing for blood cancers.18PubMed Central. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation The rationale for combination therapy is straightforward: if cancer cells can switch their dependence between BCL-2 and Mcl-1, blocking both at once should leave them with fewer escape routes. That combined approach, though logical, also compounds the toxicity concerns.
The Heart Safety Hurdle
The same features that make Mcl-1 essential for normal tissues make it a liability to inhibit systemically. The most worrisome safety signal has come from the heart. Deleting Mcl-1 specifically in cardiac muscle cells in mice caused a rapidly fatal dilated cardiomyopathy: the heart lost its ability to contract, mitochondria in the heart muscle became structurally abnormal, and mitochondrial respiration failed.19PubMed Central. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction The damage was not just about apoptosis; it reflected the loss of Mcl-1’s role in maintaining mitochondrial health, the same function described earlier in the mitochondrial matrix.
These findings cast a long shadow over clinical development. Heart muscle cells are long-lived, do not regenerate easily, and depend on continuous mitochondrial function to sustain the organ’s relentless contraction cycle. A drug that blocks Mcl-1 throughout the body could, in theory, damage the heart even at doses that effectively kill cancer cells. Several Mcl-1 inhibitors have entered early-phase clinical trials, but cardiac monitoring has become a central part of trial design. The field is watching closely for any signals of cardiac toxicity in human patients, and some researchers are exploring whether intermittent dosing schedules or tumor-targeted delivery could reduce the risk.
Picking the Right Patients with Biomarkers
Because not every cancer depends equally on Mcl-1 for survival, there is significant interest in identifying which patients are most likely to benefit from Mcl-1-targeting therapies. One approach measures the amount of Mcl-1 bound to BIM, a pro-death protein that Mcl-1 neutralizes. The presence of high levels of these Mcl-1/BIM complexes indicates that a cancer cell is “primed” for death through the Mcl-1 pathway and would likely respond to Mcl-1 inhibition.20Journal of Clinical Oncology. Identifying Mcl-1 protein dependencies using dimerization-specific antibody biomarker for predicting response to targeted apoptosis inducing therapies
A related technique, called BH3 profiling, exposes cancer cells from a patient’s bone marrow to small peptides that mimic the pro-death signals blocked by different BCL-2 family members. If the cells respond strongly to the peptide that specifically tests Mcl-1 dependence, the patient is considered Mcl-1-dependent. In a study of AML patients, those whose leukemia cells showed Mcl-1 dependence scores of 40% or higher had significantly better responses to alvocidib, a drug that indirectly reduces Mcl-1 levels, compared with patients whose cells scored low (median scores of 45% in responders versus 5% in non-responders).21Oncology Times. A Novel Biomarker Approach in MCL-1 Dependent Relapsed/Refractory AML This biomarker-guided approach led to the Zella 201 trial, which used the 40% threshold to select patients for treatment, with results expected from fresh bone marrow samples within about 48 hours.22Blood. Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
The ability to measure Mcl-1 dependence before treatment starts represents a meaningful shift in how these therapies could be deployed. Rather than giving every patient the same regimen and hoping for the best, clinicians could route patients toward Mcl-1-targeted strategies only when the tumor’s biology indicates a strong dependence on that protein. Biomarker-guided selection is still being validated in larger trials, but the early data suggest it can separate likely responders from likely non-responders far more effectively than demographic or clinical characteristics alone.
When Cancer Cells Resist Mcl-1 Inhibitors Too
Resistance is a recurring theme in cancer treatment, and Mcl-1 inhibitors are no exception. Even when a drug successfully blocks Mcl-1, cancer cells can rewire their survival circuitry. In breast cancer cells that acquired resistance to an Mcl-1 inhibitor, researchers found that Mcl-1 inhibition led to a decrease in BIM (the pro-death protein) while simultaneously increasing BCL-2 levels. The result was a swap of dependencies: the cell abandoned Mcl-1 as its lifeline and leaned on BCL-2 instead. Blocking ERK signaling reversed this shift, restoring BIM and reducing BCL-2, which killed the resistant cells.23Cell Signaling. Potential biomarkers for MCL1 inhibitor sensitivity
This kind of resistance underscores why combination strategies are being pursued so aggressively. If a cancer cell can swap its survival dependence from Mcl-1 to BCL-2 or BCL-XL when one pathway is blocked, the logical response is to block multiple pathways simultaneously or to pair Mcl-1 inhibition with drugs that prevent the compensatory upregulation. Identifying the signaling pathways that mediate these resistance switches, ERK being one of the clearest so far, could also open the door to three-drug combinations that cut off escape routes before the cancer cell can use them.
Liver Damage as a Window Into Cancer Origins
One of the more counterintuitive findings about Mcl-1 comes from the liver. When researchers deleted Mcl-1 only in hepatocytes, the immediate result was widespread spontaneous apoptosis and severe liver injury. But because the liver has remarkable regenerative capacity, the remaining cells proliferated to compensate, and over time this chronic cycle of death and compensatory growth led to the development of liver tumors.5PubMed Central. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice The irony is hard to miss: losing a protein that cancer cells rely on for survival actually caused cancer in this context, because the tissue damage triggered relentless regeneration that eventually went wrong.
This finding is a reminder that the relationship between cell death and cancer is not always linear. Too little apoptosis lets damaged cells survive and accumulate mutations. But too much apoptosis in a regenerative tissue can drive the same outcome through a different route, by forcing surviving cells to divide so often that mutations become inevitable. The Mcl-1 liver model is one of the clearest demonstrations of this paradox, and it adds another layer of caution to therapeutic strategies that aim to reduce Mcl-1 levels systemically over extended periods.